• LeroyPerseHK's Avatar

    LeroyPerseHK shared a photo


    At this point all we can do is hope! I hope you all are staying safe from others who might be a carrier.

  • LeroyPerseHK's Avatar

    LeroyPerseHK asked a questionBladder Cancer

    Someone asked me if I "had all my ducks in a row" and was ready for the surgery and other things coming.

    4 answers
    • Bengal's Avatar

      I have a big old fashion paper calendar with large squares for every date. I write everything on it and keep it on the corner of my kitchen table. Every morning when I get up it's the first thing I do. Check to see where I need to be today. For the most important things I also put stickers on the calendar as an extra reminder.I

      One thing that makes me go balistic? When people come to my house and put their stuff down on top of THE calendar.

      about 1 year ago
    • BoiseB's Avatar

      I had a journal that I got from the Livestrong Foundation. It had calendars and pockets for papers and business cards. I have now a small binder that has plastic sleeves that can hold a magazine. I put all my current medical records, in those. I also can print out a blank calendar or purchase one from Office Depot and put it in the sleeve I have purchased a couple of those pencil bags for pens and pencils and another one for cards and prescriptions. I also keep a general calendar in my purse so I don't overbook. I also keep an address list in the binder also it is a good place to keep a list of questions for the Dr.

      about 1 year ago
    • Whitey61's Avatar

      Small pocket calendar that I carry with Wallet everywhere.. Medical appts, part time work, my own business appts I would be lost....don't like the cellphone option.

      about 1 year ago
  • LeroyPerseHK's Avatar
  • LeroyPerseHK's Avatar

    LeroyPerseHK shared a photo


    I believe this is as true a statement that's ever been said.

  • LeroyPerseHK's Avatar

    LeroyPerseHK posted an update

    The Top 10 Cancers of America
    Here are the most common cancers in the United States. Most of these statistics were compiled in the American Cancer Society Facts & Figures annual report for 2013.

    1 – Skin cancer

    Skin cancer is divided into the non-melanoma and melanoma categories. Non-melanoma (basal cell and squamous cell skin cancer) is the more common form with over 2,000,000 cases expected to be diagnosed in the country in 2012. Most of these forms of cancer are curable. Melanoma, on the other hand, is the more serious type of skin cancer. It affects approximately five percent of people diagnosed with skin cancer, but is attributed to over 75 percent of all skin cancer deaths. In 2012, 76,250 new cases of melanoma were expected to be diagnosed.

    2 – Lung cancer

    During 2012, 226,160 new cases of lung cancer were expected to be diagnosed in the U.S. Lung cancer accounts for about 28 percent of all cancer deaths. An estimated 160,340 deaths were expected to occur from lung cancer in 2012. The 5-year survival rate for all stages of lung cancer combined is just 16 percent. However, for cases detected when the disease is still localized, that number is 53 percent. Cigarette smoking is the most important risk factor for lung cancer.

    3 – Prostate cancer

    It’s estimated that 1 in 6 men in the U.S. will be diagnosed with prostate cancer in their lifetime. It’s the most commonly diagnosed cancer among men (excluding skin cancer) and the second most common cause of death. Approximately 241,740 new cases were diagnosed in 2012 with an estimated 28,170 men expected to die from the disease in the year. PSA screenings and digital rectal exams (DRE) can help for early detection.

    4 – Breast cancer

    According to the American Cancer Society, 226,870 new cases of invasive breast cancer were expected to occur during 2012 in the U.S. Excluding skin cancer, breast cancer is the most frequently diagnosed cancer among women. Breast cancer ranks second as a cause of cancer death in women (after lung cancer).

    5 – Colorectal cancer

    An estimated 103,170 new cases of colon and 40,290 cases of rectal cancer were expected to occur in 2012. Colorectal cancer doesn’t discriminate — it’s the third most common cancer in both men and women. Colorectal cancer was expected to account for nine percent of all cancer deaths in 2012.

    6 – Kidney (renal) cancer

    The American Cancer Society estimated 64,770 new cases of kidney (renal) cancer in 2012 with 13,570 deaths from this disease. Tobacco is a strong risk factor for kidney cancer, as well as obesity and hypertension.

    7 – Bladder cancer

    Blood in the urine is a common symptom of urinary bladder cancer. An estimated 73,510 new cases of this cancer were expect in 2012. With all stages of bladder cancer combined, the five-year relative survival rate is 80 percent. Surgery (alone or in conjunction with other treatments) is used in 90 percent of cases.

    8 – Non-Hodgkin’s lymphoma

    As you may know, one of the common symptoms of non-Hodgkin’s lymphoma (NHL) is swollen lymph nodes. About 30 different kinds of NHL exist. It was estimated that 70,130 new cases of this type of cancer would be diagnosed in 2012.

    9 – Thyroid cancer

    Three out of four cases of thyroid cancer occur in women. Perhaps surprisingly, it is the fastest-increasing cancer in both men and women. A lump in the neck is the most common symptom of thyroid cancer. An estimated 56,460 new cases of thyroid cancer were expected in 2012 in the U.S., as well as 1,780 deaths from the disease.

    10 – Endometrial cancer

    Cancer of the uterine corpus usually occurs in the endometrium (uterus lining). Abnormal bleeding is often an early sign of this type of cancer. In 2012, the American Cancer Society estimated 47,130 new cases of uterine corpus cancer. Treatment can include surgery, radiation, chemotherapy and/or hormonal methods, depending on the stage of the cancer.

    Other common cancers

    Also called exocrine cancer, pancreatic cancer often develops without early symptoms. The survival rates for all stages combined are 25 percent for one year and 6 percent for five years. Approximately 43,920 new cases were expected in 2012 along with an estimated 37,390 deaths. Leukemia is also a fairly common cancer in the U.S. with an estimated 47,150 new cases in 2012.

    To learn more about the various types of cancer, causes, symptoms and treatment options, visit cancer.org, cancer.gov and other online cancer websites.

  • LeroyPerseHK's Avatar

    LeroyPerseHK posted an update

    The FDA office that reviews applications for cancer therapies has been renamed and reorganized.

    The Center for Drug Evaluation and Research’s Office of Oncologic Diseases — formerly known as the Office of Hematology and Oncology Products — now is structured under terms of a modernization plan approved last fall.

    Richard Pazdur, MD — who served as director of the Office of Hematology and Oncology Products since 2005 — will serve as acting director of the reorganized entity.

    “As the practice of oncology and the treatments for these life-threatening diseases have become more complex, we recognized the need to flatten the organization with additional but smaller review divisions to enable more efficient drug review,” Pazdur said in an FDA-issued press release. “Reorganizing the office in this manner will allow for greater stakeholder engagement in the various disease programs.”

    The old structure consisted of three clinical divisions and one nonclinical division.

    The new structure includes six divisions.

    • Division of Oncology 1 will be responsible for breast, gynecologic and genitourinary cancers, as well as supportive care.

    • Division of Oncology 2 will review products for head and neck cancers, thoracic cancers, central nervous system cancers, pediatric solid tumors and rare cancers.

    • Division of Oncology 3 will review products for melanoma and other skin cancers, gastrointestinal cancers and sarcomas.

    • Division of Hematologic Malignancies 1 will be responsible for products for acute leukemia and myelodysplasia, chronic myeloid leukemia and other myeloproliferative neoplasms with the term “leukemia,” and blastic plasmacytoid dendritic cell neoplasm; conditioning regimens for these indications; graft-versus-host disease, cytokine release syndrome, tumor lysis syndrome and chimeric antigen receptor T-cell therapy neurotoxicity.

    • Division of Hematologic Malignancies 2 will review products for lymphoma, chronic lymphocytic leukemia, multiple myeloma and other plasma cell malignancies.

    • Division of Hematology Oncology Toxicology remains unchanged.

    The newly formed Division of Non-malignant Hematology — part of the Office of Cardiology, Hematology, Endocrinology and Nephrology — will review products for benign hematologic diseases and other conditions.